Doximity, Inc. Class A Common Stock (NY:DOCS)

27.93 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Doximity, Inc. Class A Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

30 31 Next >

6 Analysts Assess Doximity: What You Need To Know ↗

April 23, 2024

Via Benzinga

Doximity, Inc. (DOCS) Investor Notice: Robbins LLP Reminds Stockholders of the Doximity, Inc. Shareholder Class Action

April 22, 2024

From Robbins LLP

Via Business Wire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Doximity

April 22, 2024

From Faruqi & Faruqi LLP

Via GlobeNewswire

DOXIMITY, INC. (NYSE: DOCS) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Doximity, Inc. Investors of Upcoming Deadline

April 22, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

NYSE:DOCS—Positioned as a High-Growth Stock, Ready for a Potential Breakout. ↗

April 12, 2024

Via Chartmill

6 Analysts Assess Doximity: What You Need To Know ↗

April 02, 2024

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Luna, HireRight, and Doximity Innovations and Encourages Investors to Contact the Firm

April 21, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

DOXIMITY SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCS

April 19, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Doximity, Inc. (DOCS) Investors

April 19, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

NYSE:DOCS, a growth stock which is not overvalued. ↗

March 22, 2024

Investors should take note ofDOXIMITY INC-CLASS A (NYSE:DOCS), a growth stock that remains attractively priced.

Via Chartmill

What 6 Analyst Ratings Have To Say About Doximity ↗

March 15, 2024

Via Benzinga

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the Firm

April 18, 2024

From Schall Law

Via GlobeNewswire

DOXIMITY, INC. (NYSE: DOCS) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Doximity, Inc.

April 18, 2024

From Bernstein Liebhard LLP

Via GlobeNewswire

DOCS INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Doximity, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

April 18, 2024

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

NYSE:DOCS—A High-Growth Stock Gearing Up for Its Next Upward Move. ↗

March 12, 2024

Why DOXIMITY INC-CLASS A (NYSE:DOCS) Is a Promising High-Growth Stock in the Midst of Consolidation.

Via Chartmill

NYSE:DOCS stands out as a growth opportunity that won't break the bank. ↗

February 29, 2024

Investors seeking growth at a reasonable cost should explore NYSE:DOCS.

Via Chartmill

DOXIMITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Doximity, Inc. and Encourages Investors to Contact the Firm

April 17, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Against Doximity, Inc. (DOCS)

April 17, 2024

From Robbins LLP

Via GlobeNewswire

Investor Alert: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Doximity, Inc. and Encourages Investors With Losses to Contact the Firm (NYSE: DOCS)

April 17, 2024

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

Forecasting The Future: 5 Analyst Projections For Doximity ↗

February 26, 2024

Via Benzinga

For those who appreciate growth without the sticker shock, NYSE:DOCS is worth considering. ↗

April 15, 2024

DOXIMITY INC-CLASS A (NYSE:DOCS) stands out as a growth opportunity that won't break the bank.

Via Chartmill

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

April 05, 2024

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

April 05, 2024

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Doximity, Inc. (DOCS) on Behalf of Investors

April 03, 2024

From The Law Offices of Frank R. Cruz

Via Business Wire

DOXIMITY ALERT: Bragar Eagel & Squire, P.C. is Investigating Doximity, Inc. on Behalf of Doximity Stockholders and Encourages Investors to Contact the Firm

April 02, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

ROSEN, LEADING INVESTOR COUNSEL, Encourages Doximity, Inc. Investors to Inquire About Securities Class Action Investigation – DOCS

April 01, 2024

From The Rosen Law Firm, P.A.

Via Business Wire

HIMS Stock Breaks Out On Powerful Turnaround Quarter ↗

February 27, 2024

"In 2024, we expect to eclipse $1 billion in revenue and deliver our first full year of net income profitability.": CEO Andrew Dudum

Via Investor's Business Daily

Doximity to Participate in Upcoming Investor Events

February 22, 2024

From Doximity

Via Business Wire

2 Beaten-Down Stocks to Buy and Hold for 10 Years ↗

February 21, 2024

One is a longtime healthcare leader, the other a newcomer; both have bright futures despite recent obstacles.

Via The Motley Fool

1 Cash-Gushing Stock Down 70% to Buy and Hold Forever ↗

February 21, 2024

This healthcare upstart, with a free-cash-flow margin of 27% even after removing stock-based compensation, deserves a long look from investors.

Via The Motley Fool

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.